Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more
Zhejiang Orient Gene Biotech Co Ltd (688298) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.005x
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has a cash flow conversion efficiency ratio of -0.005x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-30.52 Million) by net assets (CN¥6.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zhejiang Orient Gene Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasa Marga Tbk
JK:JSMR
|
0.041x |
|
Syncmold Enterprise Corp
TW:1582
|
0.036x |
|
Molinos Agro SA
BA:MOLA
|
-1.906x |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
-0.031x |
|
AGF Management Limited
PINK:AGFMF
|
0.036x |
|
BKS Bank AG
VI:BKS
|
-0.098x |
|
Pet Acquisition LLC
NASDAQ:WOOF
|
0.078x |
|
Sprout Social Inc
NASDAQ:SPT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.79 Billion | CN¥-348.33 Million | -0.051x | +75.83% |
| 2023-12-31 | CN¥7.55 Billion | CN¥-1.60 Billion | -0.212x | -158.95% |
| 2022-12-31 | CN¥8.32 Billion | CN¥3.00 Billion | 0.360x | -52.35% |
| 2021-12-31 | CN¥6.89 Billion | CN¥5.20 Billion | 0.755x | +3.44% |
| 2020-12-31 | CN¥2.45 Billion | CN¥1.79 Billion | 0.730x | +242.35% |
| 2019-12-31 | CN¥254.13 Million | CN¥54.21 Million | 0.213x | +0.12% |
| 2018-12-31 | CN¥208.03 Million | CN¥44.33 Million | 0.213x | -12.27% |
| 2017-12-31 | CN¥138.12 Million | CN¥33.54 Million | 0.243x | +103.04% |
| 2016-12-31 | CN¥98.72 Million | CN¥11.81 Million | 0.120x | -- |